WO2001023364A1 - Quinazolinones - Google Patents

Quinazolinones Download PDF

Info

Publication number
WO2001023364A1
WO2001023364A1 PCT/EP2000/008939 EP0008939W WO0123364A1 WO 2001023364 A1 WO2001023364 A1 WO 2001023364A1 EP 0008939 W EP0008939 W EP 0008939W WO 0123364 A1 WO0123364 A1 WO 0123364A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
cyclohexylmethyl
aminomethyl
quinazolin
compounds
Prior art date
Application number
PCT/EP2000/008939
Other languages
French (fr)
Inventor
Werner Mederski
Ralf Devant
Gerhard Barnickel
Sabine Bernotat-Danielowski
Guido Melzer
Daljit Dhanoa
Bao-Ping Zhao
James Rinker
Mark Player
Richard Soll
Bertram Cezanne
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Priority to US10/089,167 priority Critical patent/US7060706B1/en
Priority to KR1020027003906A priority patent/KR20020047185A/en
Priority to BR0014311-1A priority patent/BR0014311A/en
Priority to CA002385918A priority patent/CA2385918A1/en
Priority to EP00962482A priority patent/EP1216233A1/en
Priority to AU74193/00A priority patent/AU7419300A/en
Publication of WO2001023364A1 publication Critical patent/WO2001023364A1/en
Priority to NO20021503A priority patent/NO20021503D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the invention relates to substituted quinazoiinones of the formula
  • R and R 1 are independently of each other H, A, OH, OA, OCH 2 -Ar, Hal,
  • R 4 is Ar, phenylalkyl, cycloalkyl or Het, Y may be absent and, if present, is alkenyl having 2 to 4 carbon atoms,
  • A is unbranched or branched alkyl having 1 to 6 carbon atoms
  • Ar is phenyl, naphthyl, biphenyl or benzofuranyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA,
  • CF 3 OCF 3 , Hal, CN, COOH, COOA, NH 2 , NHA, NA 2 , NO 2 ,
  • Het is a saturated, partially or completely unsaturated mono- or bicyclic heterocyclic radical having 5 to 10 ring members, where 1 or 2 N and/or 1 or 2 S or O atoms can be present and the heterocyclic radical can be mono- or disubstituted by A,
  • NA 2 , NO 2 , SO 2 NH 2 , SO 2 NAH or SO 2 NA 2 or thiophenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF 3 , OCF 3 , Hal, CN, COOH, COOA, NH 2 , NHA, NA 2 , NO 2 ,
  • the invention is based on the object of finding novel compounds having valuable properties, in particular those which can be used for the production of medicaments.
  • the compounds of the formula I and their salts or solvates have very valuable pharmacological properties together with good tolerability. They act especially as GPIblX inhibitors, in particular inhibiting the interaction of this receptor with the ligand von Willebrand factor (vWF). This action can be demonstrated, for example, by a method which is described by S. Meyer et al. in J. Biol. Chem. 1993, 268, 20555-20562. The property as GPIblX alpha-thrombin receptor (N.J. Greco, Biochemistry 1996, 35, 915-921) can also be blocked by the compounds mentioned.
  • GPIblX as an adhesion receptor on platelets, which mediates the primary interaction of platelets with an arteriosclerotically modified vascular wall via binding to the vWF expressed there, has been described by many authors (e.g. Z.M. Ruggeri in Thromb. Hemost. 1997, 78, 611-616).
  • GPIIbllla another platelet adhesion receptor, GPIIbllla, following the GPIblX-vWF interaction, leads to platelet aggregation and thus to thrombotic vascular occlusion.
  • a GPIblX antagonist can thus prevent the start of thrombus formation and thus also release of active substances from the platelets which, for example, promote thrombus growth and have an additional trophic action on the vascular wall. This has been shown with inhibitory peptides or antibodies in various experimental models (e.g. H Yamamoto et al., Thromb. Hemost. 1998, 79, 202-210).
  • the blocking action of GPIblX inhibitors exerts its maximum effect, as described by J.J. Sixma et al. in Arteriosclerosis, Thrombosis, and Vascular Biology 1996, 16, 64-71.
  • the compounds of the formula I can be characterized as GPIblX inhibitors in whole blood.
  • the inhibition of thrombus formation of the GPIblX inhibitors can be measured by a modified Born method (Nature 1962, 4832, 927-929) using botrocetin or ristocetin as an aggregation stimulant.
  • the compounds of the formula I according to the invention can therefore be employed as pharmaceutical active compounds in human and veterinary medicine. They act as adhesion receptor antagonists, in particular as glycoprotein IblX antagonists, and are suitable for the prophylaxis and/or therapy of thrombotic disorders and sequelae deriving therefrom.
  • adhesion receptor antagonists in particular as glycoprotein IblX antagonists
  • glycoprotein IblX antagonists are suitable for the prophylaxis and/or therapy of thrombotic disorders and sequelae deriving therefrom.
  • the preferentially best action is to be expected in the case of thrombotic disorders in the arterial vascular system, but GPIblX inhibitors also have an effect in the case of thrombotic disorders in the venous vascular bed.
  • the disorders are acute coronary syndromes, angina pectoris, myocardial infarct, peripheral circulatory disorders, stroke, transient ischaemic attacks, arteriosclerosis, reocclusion/restenosis after angioplasty/stent implantation.
  • the compounds can furthermore be employed as anti-adhesive substances where the body comes into contact with foreign surfaces such as implants, catheters or cardiac pacemakers.
  • the invention relates further to compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates as pharmaceutical active compounds.
  • the invention relates to the compounds of the formula I and their salts or solvates, and to a process for the preparation of these compounds and their salts or solvates, characterized in that
  • a compound of the formula I is liberated from one of its functional derivatives by treating with a solvolysing or hydrogenolysing agent, or b) in stage 1) a compound of the formula II
  • solid phase indicates a resin for solid-phase chemistry, especially for combinatorial chemistry, i.e. by robot- and computer-assisted syntheses, and subjected to mass screening as indicated in US 5,463,564; M. A. Gallop et al., J. Med. Chem. 1994, 37, 1233-1251 and 1385-1401 and M.J. Sofia, Drugs Discovery Today 1996, 1 , 27-34).
  • the polymeric material of the solid phase is generally chosen from the group consisting of cross-linked polystyrene, cross-linked polyacrylamide or other resins, natural polymers or silicagels.
  • R 4 is Ar, phenylalkyl, cycloalkyl or Het, where Ar, phenylalkyl, cycloalkyl or Het have a preferred meaning indicated beforehand.
  • R 4 is preferentially phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 4-tert- butylphenyl, 4-dimethylaminophenyl, 4-methoxyphenyl, 3-methoxyphenyl, 3-chlorophenyl, 3,4,5-trimethoxyphenyl, 3,4-dimethoxyphenyl, 2,5- dimethoxyphenyl, 3',5'-dimethoxybiphenyl-4-yl, 2',4'-dimethoxybiphenyl-4- yl, biphenyl-4-yl, naphthalen-1-yl, naphthalen-2-yl or benzofuran-5-yl, phenylethyl, cyclohexy
  • Y is absent
  • R 3 is H, Y is absent,
  • -COOH carry a group -COOR", in which R" is a hydroxyl protective group.
  • acyl groups derived from aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids and, in particular, alkoxycarbonyl groups, aryloxycarbonyl groups and especially aralkoxycarbonyi groups.
  • hydroxyl protective groups are, inter alia, benzyl, 4-methoxybenzyl oder 2,4-dimethoxybenzyl, aroyl groups such as benzoyl or p-nitrobenzoyl, acyl groups such as acetyl or pivaloyl, p-toluolsulfonyl, alkyl groups such as methyl or tert-butyl, but also allyl, alkylsilyl groups such as trimethylsilyl (TMS), triisopropylsilyl (TIPS), tert-butyldimethylsilyl (TBS) or triethylsilyl, trimethylsilylethyl, aralkylsilyl groups such as tert-butyldiphenylsilyl (TBDPS), cyclic acetals such as isopropylidene-, cyclopentylidene-, cyclohexylidene-, benzyliden
  • the solid phase with a carbonate moiety as terminal functional group can preferably be removed, for example, using TFA (50%) in dichloromethane.
  • the reactions and the attachment to the resin are carried out in an inert solvent.
  • the reaction time is between a few minutes and a number of days, the reaction temperature between approximately 0° and 150°C, normally between 20° and 130°C.
  • the reaction of the compounds of formula II with compounds of formula III is analoguesly to the coupling of peptides.
  • the condensation reaction of formula II with formula III is preferrably carried out in an inert solvent as indicated above in the presence of a dehydrating agent, such as, dicyclohexylcarbodiim.de (DCC), N-(3-dimethylaminopropyl)-N'-ethyl- carbodiimide-hydrochlo d (EDC) or diisopropylcarbodiimide (DIC), further for instance in the presence af an anhydride of propanphosphonic acid (see Angew. Chem. 1980, 92, 129), diphenylphosphorylazide or 2-ethoxy- N-ethoxycarbonyl-1 ,2-dihydroquinoline.
  • a dehydrating agent such as, dicyclohexylcarbodiim.de (DCC), N-(3-dimethylaminopropyl)
  • a coupling agent such as TBTU (O-(benzotriazol-1-yl)-N,N,N',N'-bis-(tetramethylene)-uronium tetrafluoroborate) or O-(benzotriazol-1-yl)-N,N,N',N'-bis-(tetramethylene)- uronium hexafluorophosphate.
  • a compound of formula II in which X is a reactive esterified OH group can be synthesized by reacting a compound of formula II in which X is OH with HOBt (1-hydroxybenzotriazole) or N-hydroxysuccinimide(e.g. in the standard works such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart).
  • a compond of formula I in which R 2 and R 3 are H can be treated with an amidinating agent.
  • the preferred amidinating agent is 1-amidino-3,5-dimethylpyrazole (DPFN), which is employed, in particular, in the form of its nitrate, or pyrazole-1-carboxamidine.
  • DPFN 1-amidino-3,5-dimethylpyrazole
  • the reaction is expediently carried out with addition of a base such as triethylamine or ethyldiisopropylamine in an inert solvent or solvent mixture, e.g. DMF at temperatures between 0° and 150°C, preferably between 60° and 120°C.
  • Pd(P(Ph) 3 ) 2 , Pd(ll)CI 2 dppf, PdOAc 2 + P(R * ) 3 (R * phenyl, cyclohexyl, tert-butyl) etc. in the presence of a base such as potassium carbonate, caesium carbonate, DBU, NaOH, in an inert solvent or solvent mixture, e.g. DMF or 1 ,4-dioxane at temperatures between 0° and 150°, preferably between 60° and 120°. Depending on the conditions used, the reaction time is between a few minutes and a number of days.
  • the boronic acid derivatives can be prepared by conventional methods or are commercially available.
  • a base of the formula I can be converted into the associated acid addition salt using an acid, for example by reaction of equivalent amounts of the base and of the acid in an inert solvent such as ethanol and subsequent evaporation.
  • Acids which give physiologically acceptable salts are particularly suitable for this reaction.
  • inorganic acids can be used, e.g. sulfuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, furthermore organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulfonic or sulfuric acids, e.g.
  • the invention furthermore relates to pharmaceutical preparations comprising at least one compound of the formula I and/or one of its physiologically acceptable salts, which are prepared, in particular, in an non-chemical way.
  • the compounds of the formula I can be brought into a suitable dose form together with at least one solid, liquid and/or semi-liquid excipient or auxiliary and, if appropriate, in combination with one or more other active compounds.
  • preparations can be used as medicaments in human or veterinary medicine.
  • Possible excipients are organic or inorganic substances which are suitable for enteral (e.g. oral) or parenteral administration or topical application and do not react with the novel compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glyceryl triacetate, gelatin, carbohydrates such as lactose or starch, magnesium stearate, talc and petroleum jelly.
  • Tablets, pills, coated tablets, capsules, powders, granules, syrups, juices or drops are used, in particular, for oral administration, suppositories are used for rectal administration, solutions, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants, are used for parenteral administration, and ointments, creams or powders are used for topical application.
  • the novel compounds can also be lyophilized and the lyophilizates obtained used, for example, for the production of injection preparations.
  • the daily dose is preferably between approximately 0.02 and 10 mg/kg of body weight.
  • the specific dose for each patient depends, however, on all sorts of factors, for example on the efficacy of the specific compound employed, on the age, body weight, general state of health and sex, on the diet, on the time and route of administration, and on the excretion rate, pharmaceutical combination and severity of the particular disorder to which the therapy applies. Oral administration is preferred.
  • customary working-up for solution reactions means: if necessary, water is added, if necessary, depending on the constitution of the final product, the mixture is adjusted to pHs between 2 and 10 and extracted with ethyl acetate or dichloromethane, the organic phase is separated off, dried over sodium sulfate and evaporated, and the residue is purified by chromatography on silica gel and/or by crystallization.
  • R 2 and R 3 are H, excluding C-(3-aminomethyi-cyclohexyl)- methylamine, and n and m have the meanings indicated in Claim 1 the following resin bound bis amines are obtained: cyclohexane-1 ,3-diamine, resin bound;
  • Example 11 Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with naphthalene-2-carbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained
  • R' 4-CI in formula lla 3-(3-aminomethyl-cyclohexylmethyl)-2-styryl-7-chloro-3H-quinazolin-4-one;
  • Example 13 Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with benzofuran-5-carbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained
  • R' 4-CI in formula lla 3-(3-aminomethyl-cyclohexylmethyl)-2-[2-(2,5-dimethyoxy-phenyl)-vinyl]-7- chloro-3H-quinazolin-4-one;
  • R' H in formula lla 3-(3-aminomethyl-cyclohexylmethyl)-2-(2',4'-dimethoxy-biphenyl-4-yl)-3H- quinazolin-4-one.
  • reaction is then treated with 1.62 mmol Cs 2 CO 3 , 1.62 mmol of 2,4- dimethoxyphenyl boronic acid and 10 mol% ([Pd 2 (dba) 3 ] + P(tert-Bu) 3 ).
  • the reaction is then allowed to shake at 80° until conversion is complete. After cooling the reaction mixture, it is worked up as is customary.
  • R' 3-CH 3 in formula lla 3-(3-aminomethyl-cyclohexylmethyl)-2-[5-(2,4-dimethoxy-phenyl)-2- thiophenyl]-6-methyl-3H-quinazolin-4-one;
  • a solution of 100 g of an active compound of the formula I and 5 g of disodium hydrogenphosphate is adjusted to pH 6.5 in 3 I of double-distilled water using 2N hydrochloric acid, sterile-filtered, dispensed into injection vials, lyophilized under sterile conditions and aseptically sealed. Each injection vial contains 5 mg of active compound.
  • Example B Suppositories
  • a solution is prepared from 1 g of an active compound of the formula I,
  • 500 mg of an active compound of the formula I is mixed with 99.5 g of petroleum jelly under aseptic conditions.
  • a mixture of 1 kg of active compound of the formula I, 4 kg of lactose, 1.2 kg of potato starch, 0.2 g of talc and 0.1 kg of magnesium stearate is compressed in a customary manner to give tablets such that each tablet contains 10 mg of active compound.
  • Example E Analogously to Example E, tablets are pressed which are then coated with a coating of sucrose, potato starch, talc, tragacanth and colourant in a customary manner.
  • a solution of 1 kg of active compound of the formula I in 60 ml of double- distilled water is sterile-filtered, dispensed into ampoules, lyophilized under sterile conditions and aseptically sealed. Each ampoule contains 10 mg of active compound.

Abstract

Quinazolinones of formula (I) in which R, R?1, R2, R3, R4¿, Y, n and m have the meaning indicated in Patent Claim 1, and their salts or solvates as glycoprotein IbIX antagonists.

Description

Quinazoiinones
The invention relates to substituted quinazoiinones of the formula
Figure imgf000002_0001
in which R and R1 are independently of each other H, A, OH, OA, OCH2-Ar, Hal,
NH2, NHA, NA2, NO2, CN, C(O)R2, CONH2, CONHA, CONA2,
COOH, COOA or SO2A,
R2 and R3 are independently of each other H, A, -C(=NH)-NH2 or solid phase,
R4 is Ar, phenylalkyl, cycloalkyl or Het, Y may be absent and, if present, is alkenyl having 2 to 4 carbon atoms,
A is unbranched or branched alkyl having 1 to 6 carbon atoms, Ar is phenyl, naphthyl, biphenyl or benzofuranyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA,
CF3, OCF3, Hal, CN, COOH, COOA, NH2, NHA, NA2, NO2,
SO2NH2, SO2NAH or SO2NA2,
Het is a saturated, partially or completely unsaturated mono- or bicyclic heterocyclic radical having 5 to 10 ring members, where 1 or 2 N and/or 1 or 2 S or O atoms can be present and the heterocyclic radical can be mono- or disubstituted by A,
Hal, OH, OA, CF3, OCF3, NH2, NHA, NA2, COOH, COOA, phenyl which is unsubstituted or mono-, di- or trisubstituted by
A, OH, OA, CF3, OCF3, Hal, CN, COOH, COOA, NH2, NHA,
NA2, NO2, SO2NH2, SO2NAH or SO2NA2 or thiophenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF3, OCF3, Hal, CN, COOH, COOA, NH2, NHA, NA2, NO2,
SO2NH2, SO2NAH or SO2NA2, Hal is F, Cl, Br or l, n is 0, 1 , 2 or 3, m is 0, 1 , 2 or 3, and their pharmaceutically tolerable salts and solvates.
Similar compounds having a quinazolinone parent structure as a combinatorial library are disclosed in WO 98/11438. W.D. Dean et al, J. Het. Chem. 1982, 1117-24 and L. Legrand et al, Bull. Soc. Chim. Fr. 1976,
1853-6 describes methods for the synthesis of similar quinazolinone compounds.
The invention is based on the object of finding novel compounds having valuable properties, in particular those which can be used for the production of medicaments.
It has been found that the compounds of the formula I and their salts or solvates have very valuable pharmacological properties together with good tolerability. They act especially as GPIblX inhibitors, in particular inhibiting the interaction of this receptor with the ligand von Willebrand factor (vWF). This action can be demonstrated, for example, by a method which is described by S. Meyer et al. in J. Biol. Chem. 1993, 268, 20555-20562. The property as GPIblX alpha-thrombin receptor (N.J. Greco, Biochemistry 1996, 35, 915-921) can also be blocked by the compounds mentioned.
The significance of GPIblX as an adhesion receptor on platelets, which mediates the primary interaction of platelets with an arteriosclerotically modified vascular wall via binding to the vWF expressed there, has been described by many authors (e.g. Z.M. Ruggeri in Thromb. Hemost. 1997, 78, 611-616). The activation of another platelet adhesion receptor, GPIIbllla, following the GPIblX-vWF interaction, leads to platelet aggregation and thus to thrombotic vascular occlusion.
A GPIblX antagonist can thus prevent the start of thrombus formation and thus also release of active substances from the platelets which, for example, promote thrombus growth and have an additional trophic action on the vascular wall. This has been shown with inhibitory peptides or antibodies in various experimental models (e.g. H Yamamoto et al., Thromb. Hemost. 1998, 79, 202-210).
In the case of higher shear forces, the blocking action of GPIblX inhibitors exerts its maximum effect, as described by J.J. Sixma et al. in Arteriosclerosis, Thrombosis, and Vascular Biology 1996, 16, 64-71. According to the flow chamber method used there, the compounds of the formula I can be characterized as GPIblX inhibitors in whole blood.
The inhibition of thrombus formation of the GPIblX inhibitors can be measured by a modified Born method (Nature 1962, 4832, 927-929) using botrocetin or ristocetin as an aggregation stimulant.
The compounds of the formula I according to the invention can therefore be employed as pharmaceutical active compounds in human and veterinary medicine. They act as adhesion receptor antagonists, in particular as glycoprotein IblX antagonists, and are suitable for the prophylaxis and/or therapy of thrombotic disorders and sequelae deriving therefrom. The preferentially best action is to be expected in the case of thrombotic disorders in the arterial vascular system, but GPIblX inhibitors also have an effect in the case of thrombotic disorders in the venous vascular bed. The disorders are acute coronary syndromes, angina pectoris, myocardial infarct, peripheral circulatory disorders, stroke, transient ischaemic attacks, arteriosclerosis, reocclusion/restenosis after angioplasty/stent implantation. The compounds can furthermore be employed as anti-adhesive substances where the body comes into contact with foreign surfaces such as implants, catheters or cardiac pacemakers.
Therefore, the invention relates further to compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates as pharmaceutical active compounds.
The invention relates to compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates as glycoprotein IblX antagonists.
Comparison medication introduced onto the market which may be mentioned are aspirin and GPIIbllla antagonists.
The invention relates to the compounds of the formula I and their salts or solvates, and to a process for the preparation of these compounds and their salts or solvates, characterized in that
a) a compound of the formula I is liberated from one of its functional derivatives by treating with a solvolysing or hydrogenolysing agent, or b) in stage 1) a compound of the formula II
Figure imgf000005_0001
in which
X is Cl, Br, OH or a reactive esterified OH group and Q is NH2 or NHA, either of which is optionally protected, and
R and R1 are optionally protected when they are or contain NH2 or NHA, is reacted with a compound of the formula III
Figure imgf000006_0001
in which R2, R3, n and m have the meanings indicated in Claim 1 , to give a compound of forumula IV
Figure imgf000006_0002
in which R, R1, R2, R3, Q, n and m have the meanings indicated above, and
15 in stage 2) a compound of formula IV as indicated above is if necessary deprotected to give a compound of formula IV in which Q is NH2 or NHA and is reacted with a compound of formula V
R -Y-CHO V ?f) in which R4 and Y have the meanings indicated in Claim 1 , or c) a radical R, R1, R2, R3 and/or R4 is converted into another radical R, R , R2, R3 and/or R4 by, for example converting an amino group into a guanidino group by reaction with 2,- an amidinating agent, reducing a nitro group, sulfonyl group or sulfoxyl group, etherifying an OH group or subjecting an OA group to ether cleavage, alkylating a primary or secondary amino group, „n - partially or completely hydrolysing a CN group, cleaving an ester group or esterifying a carboxylic acid radical, reacting an aryl bromide, aryl iodide, heteroaryl bromide or heteroaryliodide to give the corresponding coupling products by means of a Suzuki coupling with boronic acids, or carrying out a nucleophilic or electrophilic substitution, and/or a base or acid of the formula I is converted into one of its salts or solvates.
The compounds of the formula I can have a chiral centre and therefore occur in a number of stereoisomeric forms. All these forms (e.g. R and S forms) and their mixtures (e.g. the RS forms) are included in the formula I.
The compounds according to the invention also include so-called prod g derivatives, i.e. compounds of the formula I modified with, for example, alkyl or acyl groups, sugars or oligopeptides and which are rapidly cleaved in the body to give the active compounds according to the invention.
Furthermore, free amino groups as substituents of compounds of the formula I can be provided with appropriate conventional protective groups. Solvates of the compounds of the formula I are understood as meaning adducts of inert solvent molecules to the compounds of the formula I which are formed on account of their mutual power of attraction. Solvates are, for example, mono- or dihydrates or alcoholates.
The abbreviations used have the following meanings: BOC tert-butoxycarbonyl,
CBZ benzyloxycarbonyl,
DBU 1 ,8-diazabicyclo[5.4.0]undec-7-ene,
DCC dicyclohexylcarbodiimide,
DCE dichloroethane, DDQ 2,3-dichioro-5,6-dicyano-1 ,4-benzoquinone, DMA dimethylacetamide,
DMF dimethylformamide, dppf 1 , 1 '-bis(diphenylphosphino)ferrocene,
Et ethyl, Fmoc fluorenylmethoxycarbonyl,
HBTU O-(benzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluoro phosphate,
Me methyl,
Mtr 4-methoxy-2,3,6-trimethylphenylsulfonyl, OBut tert-butyl ester,
OMe methyl ester,
OEt ethyl ester,
POA phenoxyacetyl,
Ph phenyl, TEA triethylamine,
TFA trifluoroacetic acid.
In the above formulae, A is alkyl and has 1 to 6, preferably 1 , 2, 3 or 4 C atoms. Alkyl is preferably methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, additionally also pentyl, 1-, 2- or
3-methylbutyl, 1 ,1-, 1 ,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1 ,1-, 1 ,2-, 1 ,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1 ,1 ,2- or 1 ,2,2-trimethylpropyl. A is preferentially methyl.
Alkenyl having 2 to 4 carbon atoms is preferably vinyl or buta-1 ,3-dienyl; vinyl is particularly preferred. Ar is phenyl, naphthyl, biphenyl or benzofuranyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF3, OCF3, Hal, CN, COOH, COOA, NH2, NHA, NA2, NO2, SO2NH2, SO2NAH or SO2NA2.
Ar is preferentially phenyl, preferably - as indicated - mono- di- or trisubstituted phenyl, specifically preferentially phenyl, 2-, 3- or 4-methyIphenyl, 2-, 3- or 4-ethylphenyl, 2-, 3- or 4-propylphenyl, 2-, 3- or 4-isopropylphenyl, 2-, 3- or 4-tert-butylphenyl, 2-, 3- or 4-aminophenyl, 2-, 3- or 4-N,N-dimethyiaminophenyl, 2-, 3- or 4-sulfonamidophenyl, 2-, 3- or 4-nitrophenyl, 2-, 3- or 4-hydroxyphenyl, 2-, 3- or 4-methoxyphenyl, 2-, 3- or 4-ethoxyphenyl, 2-, 3- or 4-thfluoromethylphenyl, 2-, 3- or 4- trifluoromethoxyphenyl, 2-, 3- or 4-carboxyphenyl, 2-, 3- or 4-cyanophenyi, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-chlorophenyl, 2-, 3- or 4-bromophenyl. Furthermore Ar is preferentially unsubstituted naphthyl, biphenyl or benzofuran-5-yl.
Phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 4-tert- butylphenyl, 4-dimethylaminophenyl, 4-methoxyphenyl, 3-methoxyphenyl, 3-chlorophenyl, 3,4,5-trimethoxyphenyl, 3,4-dimethoxyphenyl, 2,5- dimethoxyphenyl, 3',5'-dimethoxybiphenyl-4-yl, 2',4'-dimethoxybiphenyl-4- y|, biphenyl-4-yl, naphthalen-1-yl, naphthalen-2-yl or benzofuran-5-yl is particularly preferred for Ar.
Cycloalkyl preferably has 3-7 C atoms and is preferably cyclopropyl or cyclobutyl, furthermore preferably cyclopentyl or cyclohexyl, and further also cycloheptyl; cyclohexyl is particularly preferred .
Hal is preferably F, Cl or Br.
Het is a saturated, partially or completely unsaturated mono- or bicyclic heterocyclic radical having 5 to 10 ring members, where 1 or 2 N and/or 1 or 2 S or O atoms can be present and the heterocyclic radical can be mono- or disubstituted by A, Hal, OH, OA, CF3, OCF3, NH2, NHA, NA2, COOH, COOA, phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF3, OCF3, Hal, CN, COOH, COOA, NH2, NHA, NA2, NO2, SO2NH2, SO2NAH or SO2NA2 or thiophenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF3, OCF3, Hal, CN, COOH, COOA, NH2, NHA, NA2, NO2, SO2NH2, SO2NAH or SO2NA2.
Het is preferably substituted by A, OH, OA, CF3, OCF3, Hal, CN, COOH, COOA, NH2, NHA, NA2, NO2, SO2NH2, SO2NAH or SO2NA2 or thiophenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF3, OCF3, Hal, CN, COOH, COOA, NH2, NHA, NA2, NO2, SO2NH2, SO2NAH or SO2NA2 or unsubstituted 2- or 3-furyl, 2- or 3-thiophenyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or
5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore preferably 1 ,2,3-triazol-1-, -4- or -5-yl, 1 ,2,4-triazol-1-, -4- or -5-yl, 1- or 5-tetrazolyl, 1 ,2,3-oxadiazol-4- or -5-yl, 1 ,2,4-oxadiazol-3- or -5-yl, 1 ,3,4-thiadiazol-2- or -5-yl, 1 ,2,4-thiadiazol-3- or -5-yl, 1 ,2,3-thiadiazol-4- or -5-yl, 2-, 3-, 4-, 5- or 6-2H-thiopyranyl, 2-, 3- or 4-4H-thiopyranyl, 3- or 4-pyridazinyl, pyrazinyl, 2-, 3-, 4-, 5-, 6- or 7-benzofuryl, 2-, 3-, 4-, 5-, 6- or 7-benzothienyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-1 H-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or
7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1 ,3-oxadiazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolinyl, 1-, 2-, 3-, 4- or 9-carbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl. The heterocyclic radicals can also be partially or completely hydrogenated. Het can thus also be 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or -5-furyl, tetrahydro-2- or -3-furyl, 1 ,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or
-5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -3-pyrrolyl, tetrahydro-1-, -2- or 4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4-, -5-, -6-, -7-1 H-indolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1 ,4-dihydro-1 -, -2-, -3- or -4-pyridyl,
1 ,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridyl, 1 ,2,3,6-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridyl, 1-, 2-, 3- or 4-piperidinyl, 1-, 2-, 3- or 4-azepanyl, 2-, 3- or 4-morpholinyl, tetrahydro-2-, -3- or -4-pyranyl, 1 ,4-dioxanyl, 1 ,3-dioxan-2-, -4- or -5-yl, hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1-, -2-, -4- or -5-pyrimidinyl, 1-, 2- or 3-piperazinyl, 1 ,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-quinolinyl, 1 ,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-isoquinolinyl.
2-Furyl, thiophen-2-yl, thiophen-3-yl, 5-(3,4-dimethoxyphenyl)-thiophen-2-yl or 5-[2,2']bithiophenyi is particularly preferred for Het.
Phenylalkyl preferably has 7, 8, 9 or 10 carbon atoms and is preferably phenylmethyl, phenylethyl, phenylpropyl or phenylbutyl; phenylethyl is particularly preferred .
The term solid phase indicates a resin for solid-phase chemistry, especially for combinatorial chemistry, i.e. by robot- and computer-assisted syntheses, and subjected to mass screening as indicated in US 5,463,564; M. A. Gallop et al., J. Med. Chem. 1994, 37, 1233-1251 and 1385-1401 and M.J. Sofia, Drugs Discovery Today 1996, 1 , 27-34). The polymeric material of the solid phase is generally chosen from the group consisting of cross-linked polystyrene, cross-linked polyacrylamide or other resins, natural polymers or silicagels.
The group of cross-linked polystyrene, cross-linked polyacrylamide or other resins includes e.g. polyacrylamide, polymethacrylamide, polyhydroxyethylmethacrylate, polyamide, polystyrene, (meth)acrylate copolymers, for instance from (methy)acrylic acid, esters of (meth)acrylic acid and/or 2-methylene-succinic acid, but-2-enoic acid or maleic acid, polyurethanes or other copolymers.
Suitable terminal functional groups or linkers on the surface of the resin have to be chosen to attach the compounds to the resin. There exists a variety of commercially available resins, e.g. in Novabiochem - The
Combinatorial Chemistry Catalog, March 99. Examples for sutitable resins are carbonate resins with a modified carbonate group as terminal functional group like p-nitrophenylcarbonate resin, halogenated resins like Merrifield resin (chloromethylpolystyrene) or carboxy resins like carboxy polystyrene resin or NovaSyn® TG Carboxy Resin. p-Nitrophenylcarbonate resin is particularly preferred. These and other types of resins well known in the art can be used in the subject invention.
R and R1 are independently of each other H, A, OH, OA, OCH2-Ar, Hal, NH2, NHA, NA2, NO2, CN, C(O)R2, CONH2, CONHA, CONA2, COOH,
COOA or SO2A, where A, Ar, Hal have a preferred meaning indicated beforehand and R2 has a preferred meaning indicated in the following.
R is preferentially H. R is preferentially H, A, OA or Hal. The preferred position of R1 is the 6- or 7-position of the quinazolinone ring system.
R2 and R3 are independently of each other H, A, -C(=NH)-NH2 or a solid phase, where A or solid phase have a preferred meaning indicated beforehand.
R2 is preferentially H.
R3 is preferentially H or -C(=NH)-NH2, particularly preferred is H.
R4 is Ar, phenylalkyl, cycloalkyl or Het, where Ar, phenylalkyl, cycloalkyl or Het have a preferred meaning indicated beforehand. R4 is preferentially phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 4-tert- butylphenyl, 4-dimethylaminophenyl, 4-methoxyphenyl, 3-methoxyphenyl, 3-chlorophenyl, 3,4,5-trimethoxyphenyl, 3,4-dimethoxyphenyl, 2,5- dimethoxyphenyl, 3',5'-dimethoxybiphenyl-4-yl, 2',4'-dimethoxybiphenyl-4- yl, biphenyl-4-yl, naphthalen-1-yl, naphthalen-2-yl or benzofuran-5-yl, phenylethyl, cyclohexyl, 2-furyl, thiophen-2-yl, thiophen-3-yl, 5-(3,4- dimethoxyphenyl)-thiophen-2-yl or 5-[2,2']bithiophenyl.
Y may be absent and, if present, is alkenyl having 2 to 4 carbon atoms. Y is preferentially absent or vinyl.
n and m are each independently of each other 0, 1, 2 or 3, particularly preferred 1.
Some preferred groups of compounds can be expressed by the following subformulae la to Im, which correspond to the formula I and in which the radicals not designated in greater detail have the meanings indicated in formula I, but in which in la R is H and
R1 is H, A, OA or Hal;
in lb R is H,
R1 is H, A, OA or Hal and
Y is absent;
in lc R is H, R1 isH, A, OAor Hal and
Y is alkenyl having 2 to 4 carbon atoms;
in Id R isH,
R1 isH, A, OAor Hal,
R2 is H and
R4 is Ar;
in le R isH,
R1 isH, A, OAor Hal,
R2 is H and
R4 is phenylalkyl;
in If R is H,
R1 is H, A, OAor Hal,
R2 is H and
R4 is cycloalkyl;
in Ig R is H,
R1 is H, A, OA or Hal, R2 is H and R4 is Het;
in lh R is H,
R1 is H, A, OA or Hal,
R2 is H,
R3 is H,
R4 is phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 4- tert-butylphenyl, 4-dimethylaminophenyl, 4-methoxyphenyl, 3- methoxyphenyl, 3-chlorophenyl, 3,4,5-thmethoxyphenyi, 3,4- dimethoxyphenyl, 2,5-dimethoxyphenyl, 3',5'-dimethoxy- biphenyl-4-yl, 2',4'-dimethoxybiphenyl-4-yl, biphenyl-4-yl, naphthalen-1-yl, naphthalen-2-yl or benzofuran-5-yl, phenylethyl, cyclohexyl, 2-furyl, thiophen-2-yl, thiophen-3-yl,
5-(3,4-dimethoxyphenyl)-thiophen-2-yl or 5-[2,2']bithiophenyl, n is 1 and m is 1 :
in Ik R s H,
R1 s H, A, OA or Hal,
R2 s H,
R3 s H,
Y s -CH=CH-,
R4 s phenyl, 4-dimethylaminophenyl or 2,5-dimethoxyphenyl, n s 1 and m s 1 ;
in Im R is H,
R1 is H, A, OA or Hal,
R2 is H,
R3 is H, Y is absent,
R4 is phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 4- tert-butylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, 3- chlorophenyl, 3,4,5-trimethoxyphenyl, 3,4-dimethoxyphenyl, 3',5'-dimethoxybiphenyl-4-yl, 2',4'-dimethoxybiphenyl-4-yl, biphenyl-4-yl, naphthalen-1-yl, naphthalen-2-yl or benzofuran- 5-yl, phenylethyl, cyclohexyl, 2-furyl, thiophen-2-yl, thiophen- 3-yl, 5-(3,4-dimethoxyphenyl)-thiophen-2-yl or 5- [2,2']bithiophenyl, n is 1 and m is 1.
The compounds of the formula I and also the starting substances for their preparation are otherwise prepared by methods known per se, such as are described in the literature (e.g. in the standard works such as Houben-
Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart), namely under reaction conditions which are known and suitable for the reactions mentioned. In this case, use can also be made of variants which are known per se, but not mentioned here in greater detail.
The starting substances, if desired, can also be formed in situ such that they are not isolated from the reaction mixture, but immediately reacted further to give the compounds of the formula I.
The compounds of the formula I can be obtained by liberating them from their functional derivatives by solvolysis, in particular hydrolysis or by hydrogenolysis.
Preferred starting substances for the solvolysis or hydrogenolysis are those which otherwise correspond to the formula I, but instead of one or more free amino and/or hydroxyl groups contain corresponding protected amino and/or hydroxyl groups, in particular those which instead of an H-N- group carry an R'-N- group, in which R' is an amino protective group and/or those which instead of the H atom of a hydroxyl group carry a hydroxyl protective group, e.g. those which correspond to the formula I, but instead of a group
-COOH carry a group -COOR", in which R" is a hydroxyl protective group.
A number of - identical or different - protected amino and/or hydroxyl groups can also be present in the molecule of the starting substance. If the protective groups present are different from one another, in many cases they can be removed selectively (lit.: T.W. Greene, P.G.M. Wuts, Protective Groups in Organic Chemistry, 2nd ed., Wiley, New York 1991 , P.J. Kocienski, Protecting Groups, 1st ed. or Georg Thieme Verlag, Stuttgart - New-York, 1994).
The expression "amino protective group" is generally known and relates to groups which are suitable for protecting (for blocking) an amino group against chemical reactions, but which are easily removable after the desired chemical reaction has been carried out at other positions in the molecule. Typical groups of this type are, in particular, unsubstituted or substituted acyl, aryl, aralkoxymethyl or aralkyl groups. Since the amino protective groups are removed after the desired reaction (or reaction sequence), their nature and size is otherwise not critical; however, those having 1-20, in particular 1-8, C atoms are preferred. The expression "acyl group" is to be interpreted in the widest sense in connection with the present process. It includes acyl groups derived from aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids and, in particular, alkoxycarbonyl groups, aryloxycarbonyl groups and especially aralkoxycarbonyi groups. Examples of acyl groups of this type are alkanoyl such as acetyi, propionyl, butyryl; aralkanoyl such as phenylacetyl; aroyl such as benzoyl or toluyl; aryloxyalkanoyl such as POA; alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC, 2-iodoethoxycarbonyl; aralkyloxycarbonyl such as CBZ ("carbobenzoxy"), 4-methoxybenzyloxycarbonyl (MOZ), 4-Nitro- benzyloxycarbonyl oder 9-fluorenylmethoxycarbonyl (Fmoc); 2- (phenylsulfonyl)ethoxycarbonyl; trimethylsilylethoxycarbonyl (Teoc) or arylsulfonyl such as 4-methoxy-2,3,6-trimethylphenyl-sulfonyl (Mtr). Preferred amino protective groups are BOC, furthermore CBZ, Fmoc, benzyl and acetyl; particularly preferred Fmoc.
The expression "hydroxyl protective group" is also generally known and relates to groups which are suitable for protecting a hydroxyl group against chemical reactions, but which are easily removable after the desired chemical reaction has been carried out at other positions in the molecule.
Typical groups of this type are the abovementioned unsubstituted or substituted aryl, aralkyl, aroyl or acyl groups, furthermore also alkylgroups, alkyl-, aryl- or aralkylsilylgroups or O,O- or 0,S-acetals. The nature and size of the hydroxyl protective groups is not critical, since they are removed again after the desired chemical reaction or reaction sequence; groups having 1-20, in particular 1-10 C atoms, are preferred. Examples of hydroxyl protective groups are, inter alia, benzyl, 4-methoxybenzyl oder 2,4-dimethoxybenzyl, aroyl groups such as benzoyl or p-nitrobenzoyl, acyl groups such as acetyl or pivaloyl, p-toluolsulfonyl, alkyl groups such as methyl or tert-butyl, but also allyl, alkylsilyl groups such as trimethylsilyl (TMS), triisopropylsilyl (TIPS), tert-butyldimethylsilyl (TBS) or triethylsilyl, trimethylsilylethyl, aralkylsilyl groups such as tert-butyldiphenylsilyl (TBDPS), cyclic acetals such as isopropylidene-, cyclopentylidene-, cyclohexylidene-, benzylidene-, p-methoxybenzylidene- or o,p- dimethoxybenzylideneacetal, acyclic acetales such as tetrahydropyranyl (Thp), methoxymethyl (MOM), methoxyethoxymethyl (MEM), benzyloxymethyl (BOM) or methylthiomethyl (MTM). Acetyl, benzyl, tert- butyl or TBS being particularly preferred.
The liberation of the compounds of the formula I from their functional derivatives depending on the protective group used is known in the present literature such as T.W. Greene, P.G.M. Wuts, Protective Groups in Organic Chemistry, 2nd ed., Wiley, New York 1991 , P.J. Kocienski, Protecting Groups, 1st ed., Georg Thieme Verlag, Stuttgart - New-York, 1994. In this case, use can also be made of variants which are known per se, but not mentioned here in greater detail.
The groups BOC and O-tert-butyl can preferably be removed, for example, using TFA in dichloromethane or using approximately 3 to 5N HCI in dioxane at 15-30°C, the Fmoc group using an approximately 5 to 50% solution of dimethylamine, diethylamine or piperidine in DMF at 15-30°C.
Preferred starting substances for the solvolysis or hydrogenolysis includes also those which otherwise correspond to the formula I, but are attached to a solid phase. The liberation of the compounds of the formula I from the solid phase is known in the present literature such as Novabiochem - The Combinatorial Chemistry Catalog, March 99 and cited literature.
The solid phase with a carbonate moiety as terminal functional group can preferably be removed, for example, using TFA (50%) in dichloromethane.
The quinazoiinones of formula I can also preferably be prepared, using either solution or solid-phase techniques, by combining and reacting an anthranilic acid of formula II with an amine of formula III and if necessary deprotect the given formula IV in which Q is then NH2 or NHA and reacting the compound of formul IV in which Q is NH2 or NHA with an aldehyde of formula V.
As a rule, the starting compounds of the formulae II, III and V are known or commercially available. The unknown compounds, however, can be prepared by methods known per se. The compounds of the formula II are anthranilic acids. It is furthermore possible to introduce appropriate substituents into the aromatic by conventional electrophilic or alternatively nucleophilic substitutions.
Examples of Fmoc protected anthranilic acids, include, but are not limited to, Fmoc protected anthranilic acid, Fmoc protected 3-methyl anthranilic acid, Fmoc protected 3-methoxy anthranilic acid, Fmoc protected 3-chloro anthranilic acid or Fmoc protected 4-chloro anthranilic acid.
Solid-phase techniques may be employed to condense anthranilic acids of formula II and the amine component of formula III which is resin bound (R2 or R3 is solid phase).
The amines of formula III in which R2 or R3 are H, as a rule, are also commercially available and can be attached to the suitable resin by coupling procedures well known in the art and as described in the ensuing Examples. Furthermore, syntheses for the preparation of amines of formula
111, such as, for example, the Gabriel synthesis, can be used.
The aldehydes of formula V, as a rule, are also commercially available. Furthermore, syntheses for the preparation of aldehydes of formula V, such as, for example, the oxidation of an alcohol, can be used.
As a rule, the reactions and the attachment to the resin are carried out in an inert solvent. Depending on the conditions used, the reaction time is between a few minutes and a number of days, the reaction temperature between approximately 0° and 150°C, normally between 20° and 130°C. Suitable inert solvents are, for example, hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichloroethylene, 1 ,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); ketones such as acetone or butanone; amides such as acetamide, N-methylpyrrolidone (NMP), dimethylacetamide or dimethylformarnide (DMF); nit les such as acetonitrile; sulfoxides such as dimethyl sulfoxide (DMSO); carbon disulfide; carboxylic acids such as formic acid or acetic acid; nitro compounds such as nitromethane or nitrobenzene; esters such as ethyl acetate or mixtures of the solvents mentioned.
The reaction of the compounds of formula II with compounds of formula III is analoguesly to the coupling of peptides. The condensation reaction of formula II with formula III is preferrably carried out in an inert solvent as indicated above in the presence of a dehydrating agent, such as, dicyclohexylcarbodiim.de (DCC), N-(3-dimethylaminopropyl)-N'-ethyl- carbodiimide-hydrochlo d (EDC) or diisopropylcarbodiimide (DIC), further for instance in the presence af an anhydride of propanphosphonic acid (see Angew. Chem. 1980, 92, 129), diphenylphosphorylazide or 2-ethoxy- N-ethoxycarbonyl-1 ,2-dihydroquinoline.
Particularly preferred is the presence of a coupling agent, such as TBTU (O-(benzotriazol-1-yl)-N,N,N',N'-bis-(tetramethylene)-uronium tetrafluoroborate) or O-(benzotriazol-1-yl)-N,N,N',N'-bis-(tetramethylene)- uronium hexafluorophosphate. A compound of formula II in which X is a reactive esterified OH group can be synthesized by reacting a compound of formula II in which X is OH with HOBt (1-hydroxybenzotriazole) or N-hydroxysuccinimide(e.g. in the standard works such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart).
For the preparation of compounds of the formula I in which R2 or R3 are -C(=NH)-NH-, a compond of formula I in which R2 and R3 are H can be treated with an amidinating agent. The preferred amidinating agent is 1-amidino-3,5-dimethylpyrazole (DPFN), which is employed, in particular, in the form of its nitrate, or pyrazole-1-carboxamidine. The reaction is expediently carried out with addition of a base such as triethylamine or ethyldiisopropylamine in an inert solvent or solvent mixture, e.g. DMF at temperatures between 0° and 150°C, preferably between 60° and 120°C.
For the preparation of compounds of the formula I in which R4 is unsubstituted or substituted biphenyl, 5-(3,4-dimethoxyphenyl)-thiophen-2- yl or 5-[2,2']bithiophenyl, an appropriate compound of the formula I in which R4 is phenyl chloride, phenyl bromide, phenyl iodide, thiophenyl chloride, thiophenyl bromide or thiophenyl iodide can be reacted with the appropriate boronic acid derivatives in a Suzuki type coupling reaction. This reaction is expediently carried out under Palladium catalysis with different phosphines as coordination ligands, e.g. Pd(P(Ph)3)2, Pd(ll)CI2dppf, PdOAc2 + P(R*)3 (R* = phenyl, cyclohexyl, tert-butyl) etc. in the presence of a base such as potassium carbonate, caesium carbonate, DBU, NaOH, in an inert solvent or solvent mixture, e.g. DMF or 1 ,4-dioxane at temperatures between 0° and 150°, preferably between 60° and 120°. Depending on the conditions used, the reaction time is between a few minutes and a number of days. The boronic acid derivatives can be prepared by conventional methods or are commercially available. The reactions can be carried out in analogy to the methods indicated in Suzuki et al., J. Am. Chem. Soc. 1989, 111 , 314ff., Suzuki et al., Chem. Rev. 1995, 95, 2457ff and G.C. Fu et al. Angew. Chem 1998, 110, 3586.
A base of the formula I can be converted into the associated acid addition salt using an acid, for example by reaction of equivalent amounts of the base and of the acid in an inert solvent such as ethanol and subsequent evaporation. Acids which give physiologically acceptable salts are particularly suitable for this reaction. Thus inorganic acids can be used, e.g. sulfuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, furthermore organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulfonic or sulfuric acids, e.g. formic acid, acetic acid, propionic acid, pivaiic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methane- or ethanesulfonic acid, p-toluenesulfonic acid, naphthalenemono- and disulfonic acids or laurylsulfuric acid. Salts with physiologically unacceptable acids, e.g. picrates, can be used for the isolation and/or purification of the compounds of the formula I.
On the other hand, compounds of the formula I with bases (e.g sodium or potassium hydroxide or carbonate) can be converted into the corresponding metal salts, in particular alkali metal or alkaline earth metal salts, or into the corresponding ammonium salts.
The invention furthermore relates to pharmaceutical preparations comprising at least one compound of the formula I and/or one of its physiologically acceptable salts, which are prepared, in particular, in an non-chemical way. In this case, the compounds of the formula I can be brought into a suitable dose form together with at least one solid, liquid and/or semi-liquid excipient or auxiliary and, if appropriate, in combination with one or more other active compounds.
These preparations can be used as medicaments in human or veterinary medicine. Possible excipients are organic or inorganic substances which are suitable for enteral (e.g. oral) or parenteral administration or topical application and do not react with the novel compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glyceryl triacetate, gelatin, carbohydrates such as lactose or starch, magnesium stearate, talc and petroleum jelly. Tablets, pills, coated tablets, capsules, powders, granules, syrups, juices or drops are used, in particular, for oral administration, suppositories are used for rectal administration, solutions, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants, are used for parenteral administration, and ointments, creams or powders are used for topical application. The novel compounds can also be lyophilized and the lyophilizates obtained used, for example, for the production of injection preparations. The preparations indicated can be sterilized and/or can contain auxiliaries such as lubricants, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for affecting the osmotic pressure, buffer substances, colourants, flavourings and/or one or more other active compounds, e.g. one or more vitamins.
The compounds of the formula I and their physiologically acceptable salts act as adhesion receptor antagonists, in particular glycoprotein IblX antagonists, and can be employed for the prophylaxis and/or therapy of thrombotic disorders and sequelae deriving therefrom. The disorders are acute coronary syndromes, angina pectoris, myocardial infarct, peripheral circulatory disorders, stroke, transient ischaemic attacks, arteriosclerosis and reocclusion/restenosis after angioplasty/stent implantation. ln this case, the substances according to the invention are as a rule administered in the dose of the glycoprotein llbllla antagonist ReoPro® of preferably between approximately 1 and 500 mg, in particular between 5 and 100 mg, per dose unit. The daily dose is preferably between approximately 0.02 and 10 mg/kg of body weight. The specific dose for each patient depends, however, on all sorts of factors, for example on the efficacy of the specific compound employed, on the age, body weight, general state of health and sex, on the diet, on the time and route of administration, and on the excretion rate, pharmaceutical combination and severity of the particular disorder to which the therapy applies. Oral administration is preferred.
Above and below, all temperatures are indicated in °C. In the following examples, "customary working-up" for solution reactions means: if necessary, water is added, if necessary, depending on the constitution of the final product, the mixture is adjusted to pHs between 2 and 10 and extracted with ethyl acetate or dichloromethane, the organic phase is separated off, dried over sodium sulfate and evaporated, and the residue is purified by chromatography on silica gel and/or by crystallization.
"Customary working-up" for solid-phase reactions means: the crude reaction is filtered and washed with DMF twice, then sucessively with methanol and methylene chloride three times, and finally once with methyl tert-butyl ether. The resin is then dried in vacuo.
Mass spectrometry (MS) apparatuses Kratos Maldi 111 and Finnigan LCQ. (M+H)+ values or M+ values are determined. EXAMPLES
Example 1 :
3 grams (1.62 mmol) of p-nitrophenylcarbonate resin (1) [Novabiochem: 0.54 mmol/g loading) is suspended in 30 ml of DMF then 8.1 mmol of C (3-
Aminomethyl-cyclohexy -methylamine is added at room temperature. The reaction is then heated to 55° and left to stir for two days. The crude reaction is then customary worked up for solid-phase reactions affording the resin bound bis amine (2).
Figure imgf000026_0001
Analogously, by reaction of the p-nitrophenylcarbonate resin (1) with the bis amines of formula III
Figure imgf000026_0002
in which R2 and R3 are H, excluding C-(3-aminomethyi-cyclohexyl)- methylamine, and n and m have the meanings indicated in Claim 1 the following resin bound bis amines are obtained: cyclohexane-1 ,3-diamine, resin bound;
3-aminomethyl-cyclohexylamine, resin bound;
3-aminoethyl-cyclohexylamine, resin bound; 3-aminopropyi-cyciohexylamine, resin bound; C-(3-aminoethyl-cyclohexyl)-methylamine, resin bound;
C-(3-aminopropyl-cyclohexyl)-methylamine, resin bound;
C-(3-aminoethyl-cyclohexyl)-ethylamine, resin bound;
C-(3-aminopropyl-cyclohexyl)-propylamine, resin bound; cyclohexane-1 ,4-diamine, resin bound;
4-aminomethyl-cyclohexylamine, resin bound;
4-aminoethyl-cyclohexylamine, resin bound;
4-aminopropyl-cyclohexylamine, resin bound;
C-(4-aminomethyl-cyclohexyl)-methylamine, resin bound; C-(4-aminoethyl-cyclohexyl)-methylamine, resin bound;
C-(4-aminopropyl-cyclohexyl)-methylamine, resin bound;
C-(4-aminoethyl-cyclohexyl)-ethylamine, resin bound and
C-(4-aminopropyl-cyclohexyl)-propylamine, resin bound.
Example 2:
1. Synthesis of Fmoc protected anthranilic acid
29.15 mmol of anthranilic acid is taken in 100 ml of 1 ,4 dioxane then 145 mmol of sodium bicarbonate in 20 ml of water is added. Next, 32 mmol of Fmoc-CI is added and the reaction is left to stir overnight at room temperature. The reaction is then concentrated in vacuo and customary worked up for solution reactions. The resulting solid is triturated in ethyl ether affording the pure product.
2. Coupling of Fmoc protected anthranilic acid to resin 1 gram of resin (2) is suspended in 10 ml of DMF. The reaction is then treated with 1.62 mmol of Fmoc protected anthranilic acid, 1.62 mmol of HBTU, and 1.62 mmol of triethyl amine. The reaction is then allowed to shake overnight at room temperature. After customary working up, the resin is dried in vacuo affording resin bound anthranilic acid (3).
Figure imgf000028_0001
3. Cleavage of Fmoc protected group
1 gram resin (3) is suspended in 10 ml of 20% piperidine/DMF and shaken for 1.5 hours at room temperature. The reaction is then customary worked up for solid-phase reactions affording the free aniline (4).
4. Aldehyde condensation and ring closure
100 mg resin (4) is suspended in 1 ml of dimethyl acetamide then 200 μl of acetic acid is added followed by the addition of 2.16 mmol of benzaldehyde. The reaction is then heated to 80° for two days. The reaction is then cooled to toom temperature and customary worked up for solid-phase reactions affording the resin (5).
Figure imgf000028_0002
5. Oxidation to quinazolinone
100 mg resin (5) is suspended in 4 ml solution of 36 mg of DDQ in DMF.
Then the reaction is allowed to shake overnight at room temperature. The reaction is then customary worked up for solid-phase reactions affording quinazolinone (6) resin bound.
Figure imgf000029_0001
6. Cleavage of the final product 3-(3-aminomethyl-cyclohexylmethyl)-2- phenyl-3H-quinazolin-4-one
100 mg of resin (6) is suspended in 2 ml of a 50% trifluoroacetic acid/methylene chloride solution and shaken for 1.5 hours at room temperature. Customary working up for solid-phase reactions afforded 3-(3- aminomethyl-cyclohexylmethyl)-2-phenyl-3H-quinazolin-4-one;
MS calc: 347.4 found: 348.2.
Example 3:
Analogously to example 2, by reaction of resin (2) with a compound of formula Ha
Figure imgf000029_0002
cleavage of the Fmoc protecting group and reaction with benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained with R' = 3-CI in formula Ha
3-(3-aminomethyl-cyclohexylmethyl)-6-chloro-2-phenyl-3H-quinazolin-4- one;
MS calc: 381.9 found: 382.2;
with R' = 3-CH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-methyl-2-phenyl-3H-quinazolin-4- one;
MS calc: 361.5 found: 362.2;
with R' = 4-CI in formula Ha
3-(3-aminomethyl-cyclohexylmethyl)-7-chloro-2-phenyl-3H-quinazolin-4- one;
MS calc: 381.9 found: 382.2;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-methoxy-2-phenyl-3H-quinazolin-4- one;
MS calc: 377.5.
Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with 2- methyl-benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained
with R' = 3-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-chloro-2-(2-methylphenyl)-3H- quinazolin-4-one;
MS calc: 395.9 found: 396.2; with R' = 3-CH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-methyl-2-(2-methylphenyl)-3H- quinazolin-4-one;
MS calc: 375.5 found: 376.2;
with R' = 4-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-7-chloro-2-(2-methylphenyl)-3H- quinazolin-4-one;
MS calc: 395.9 found: 396.2;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-methoxy-2-(2-methylphenyl)-3H- quinazolin-4-one;
MS calc: 391.5 found: 392.2;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-(2-methylphenyl)-3H-quinazolin-4- one;
MS calc: 361.5 found: 362.2.
Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with 3- methyl-benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained
with R' = 3-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-chloro-2-(3-methylphenyl)-3H- quinazolin-4-one;
MS calc: 395.9 found: 396.2; with R' = 3-CH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-methyl-2-(3-methylphenyl)-3H- quinazolin-4-one;
MS calc: 375.5 found: 376.2;
with R' = 4-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-7-chloro-2-(3-methylphenyl)-3H- quinazolin-4-one;
MS calc: 395.9 found: 396.2;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-methoxy-2-(3-methylphenyl)-3H- quinazolin-4-one;
MS calc: 391.5 found: 392.2;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl-2-(3-methylphenyl)-3H-quinazolin-4- one;
MS calc: 361.5 found: 362.2.
Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with 4- methyl-benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained
with R' = 3-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-chloro-2-(4-methylphenyl)-3H- quinazoiin-4-one;
MS calc: 395.9 found: 396.2; with R' = 3-CH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-methyl-2-(4-methylphenyl)-3H- quinazoiin-4-one;
MS calc: 375.5 found: 376.2;
with R' = 4-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-7-chloro-2-(4-methylphenyl)-3H- quinazolin-4-one;
MS calc: 395.9 found: 396.2;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-methoxy-2-(4-methylphenyl)-3H- quinazolin-4-one;
MS calc: 391.5 found: 392.2;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl-2-(4-methylphenyl)-3H-quinazolin-4- one;
MS calc: 361.5 found: 362.2.
Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with 4-tert- butyl-benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained
with R' = 3-CI in formula Ha
3-(3-aminomethyl-cyclohexylmethyl)-6-chloro-2-(4-tert-butylphenyl)-3H- quinazolin-4-one;
MS calc: 438.0 found: 438.2; with R' = 3-CH3 in formula lla
3-(3-aminomethyi-cyclohexylmethyl)-6-methyl-2-(4-tert-butylphenyl)-3H- quinazolin-4-one;
MS calc: 417.6 found: 418.2;
with R' = 4-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-7-chloro-2-(4-tert-butylphenyl)-3H- quinazolin-4-one;
MS calc: 438.0 found: 438.2;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-methoxy-2-(4-tert-butyiphenyl)-3H- quinazolin-4-one;
MS calc: 433.6 found: 434.2;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl-2-(4-tert-butylphenyl)-3H-quinazolin-4- one;
MS calc: 403.6 found: 404.3.
Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with 3- chloro-benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained
with R' = 3-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-chloro-2-(3-chlorophenyl)-3H- quinazolin-4-one;
MS calc: 416.4 found: 416.2; with R' = 3-CH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-methyl-2-(3-chlorophenyl)-3H- quinazolin-4-one;
MS calc: 395.9 found: 396.2;
with R' = 4-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-7-chloro-2-(3-chlorophenyl)-3H- quinazolin-4-one;
MS calc: 416.3 found: 416.2;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-methoxy-2-(3-chlorophenyl)-3H- quinazolin-4-one;
MS calc: 411.9 found: 412.1 ;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl-2-(3-chlorophenyl)-3H-quinazolin-4- one;
MS calc: 381.9 found: 382.2.
Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with 4- methoxy-benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained
with R' = 3-CI in formula Ha
3-(3-aminomethyl-cyclohexylmethyl)-6-chloro-2-(4-methoxyphenyl)-3H- quinazolin-4-one;
MS calc: 411.9 found: 412.2; with R' = 3-CH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-methyl-2-(4-methoxyphenyl)-3H- quinazolin-4-one;
MS calc: 391.5 found: 392.2;
with R' = 4-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-7-chloro-2-(4-methoxyphenyl)-3H- quinazolin-4-one;
MS calc: 411.9 found: 412.2;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-methoxy-2-(4-methoxyphenyl)-3H- quinazolin-4-one;
MS calc: 407.5 found: 408.2;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl-2-(4-methoxyphenyl)-3H-quinazolin-4- one;
MS calc: 377.5 found: 378.2.
Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with 3- methoxy-benzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained
with R* = 3-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-chloro-2-(3-methoxyphenyl)-3H- quinazolin-4-one;
MS calc: 411.9 found: 412.1 ; with R' = 3-CH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-methyl-2-(3-methoxyphenyl)-3H- quinazolin-4-one;
MS calc: 391.5 found: 392.2;
with R1 = 4-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-7-chloro-2-(3-methoxyphenyl)-3H- quinazolin-4-one;
MS calc: 411.9 found: 412.2;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexy!methyl)-6-methoxy-2-(3-methoxyphenyl)-3H- quinazolin-4-one;
MS calc: 407.5 found: 408.2;
with R' = H in formula Ha
3-(3-aminomethyl-cyclohexylmethyl-2-(3-methoxyphenyl)-3H-quinazolin-4- one;
MS calc: 377.5 found: 378.2.
Example 4:
Analogously to example 2, by reaction of resin (2) with a compound of formula lla
Figure imgf000037_0001
cleavage of the Fmoc protecting group and reaction with 3,4,5- trimethoxybenzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained
with R' = 3-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-chloro-2-(3,4,5-trimethoxyphenyl)- 3H-quinazolin-4-one;
with R' = 3-CH3 in formula lla 3-(3-aminomethyl-cyclohexylmethyl)-6-methyl-2-(3,4,5-trimethoxyphenyl)-
3H-quinazolin-4-one;
with R' = 4-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-7-chloro-2-(3,4,5-trimethoxyphenyl)- 3H-quinazolin-4-one;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-methoxy-2-(3,4,5-trimethoxyphenyl)- 3H-quinazolin-4-one;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-(3,4,5-trimethoxyphenyl)-3H- quinazoiin-4-one.
Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with 3,4- dimethoxybenzaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained
with R' = 3-CI in formula lla 3-(3-aminomethyl-cyclohexylmethyl)-6-chloro-2-(3,4-dimethoxyphenyl)-3H- quinazolin-4-one;
with R* = 3-CH3 in formula lla 3-(3-aminomethyl-cyclohexylmethyl)-6-methyl-2-(3,4-dimethoxyphenyl)-3H- quinazolin-4-one;
with R' = 4-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-7-chloro-2-(3,4-dimethoxyphenyl)-3H- quinazoiin-4-one;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-methoxy-2-(3,4-dimethoxyphenyl)- 3H-quinazolin-4-one;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-(3,4-dimethoxyphenyl)-3H- quinazolin-4-one.
Example 5:
Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with [2,2']bithiophenyl-5-carbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained
with R' = 3-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-[2,2']bithiophenyl-5-yl-6-chloro-3H- quinazolin-4-one;
MS calc: 470.1 found: 470.1 ; with R' = 3-CH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-[2,2']bithiophenyl-5-yl-6-methyl-3H- quinazolin-4-one;
MS calc: 449.6 found: 450.1 ;
with R' = 4-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-[2,2']bithiophenyl-5-yl-7-chloro-3H- quinazolin-4-one;
MS calc: 470.1 found: 470.1 ;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-[2,2']bithiophenyl-5-yl-6-methoxy-
3H-quinazolin-4-one;
MS calc: 465.6 found: 466.1 ;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-[2,2']bithiophenyl-5-yl-3H-quinazolin-
4-one;
MS calc: 435.6 found: 436.1.
Example 6:
Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with 3- furan-2-yl-propenal, oxidation and cleavage from the solid phase, the following compounds are obtained
with R' = 3-CI in formula lla 3-(3-aminomethyl-cyclohexylmethyl)-6-chloro-2-(2-furan-2-yl-vinyl)-3H- quinazolin-4-one;
MS calc: 397.9 found: 398.2;
with R' = 3-CH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-methyl-2-(2-furan-2-yl-vinyl)-3H- quinazolin-4-one;
MS calc: 377.5 found: 378.3;
with R' = 4-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyi)-7-chloro-2-(2-furan-2-yl-vinyl)-3H- quinazolin-4-one;
MS calc: 397.9 found: 398.2;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-methoxy-2-(2-furan-2-yl-vinyl)-3H- quinazolin-4-one;
MS calc: 393.5 found: 394.3;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-(2-furan-2-yl-vinyl)-3H-quinazolin-4- one;
MS calc: 363.5 found: 364.2.
Example 7:
Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with cyclohexanecarbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained with R' = 3-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-chloro-2-cyclohexyl-3H-quinazolin-4- one;
MS calc: 388.0 found: 388.2;
with R' = 3-CH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-methyl-2-cyclohexyl-3H-quinazolin-
4-one;
MS calc: 367.5 found: 368.3;
with R' = 4-CI in formula Ha
3-(3-aminomethyl-cyclohexylmethyl)-7-chloro-2-cyclohexyl-3H-quinazolin-4- one;
MS calc: 388.0 found: 388.2;
with R* = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-methoxy-2-cyclohexyl-3H- quinazolin-4-one;
MS calc: 383.5 found: 384.3;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-cyclohexyl-3H-quinazolin-4-one; MS calc: 353.5 found: 354.3.
Example 8:
Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with 3- phenyl-propionaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained with R' = 3-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-chloro-2-phenylethyl-3H-quinazolin-
4-one;
MS calc: 410.0 found: 410.3;
with R' = 3-CH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-6-methyl-2-phenylethyl-3H-quinazolin-
4-one;
MS calc: 389.5 found: 390.4;
with R' = 4-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-7-chloro-2-phenylethyl-3H-quinazolin-
4-one;
MS calc: 410.0 found: 410.3;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyl-cyciohexylmethyl)-6-methoxy-2-phenylethyl-3H- quinazolin-4-one;
MS calc: 405.5 found: 406.3;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-phenylethyl-3H-quinazolin-4-one; MS calc: 375.5 found: 376.4.
Example 9:
Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with biphenyl-4-carbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained with R' = 3-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-biphenyl-4-yl-6-chloro-3H- quinazolin-4-one;
MS calc: 458.0 found: 458.2;
with R' = 3-CH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-biphenyl-4-yl-6-methyl-3H- quinazolin-4-one;
MS calc: 437.6 found: 438.2;
with R' = 4-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-biphenyl-4-yl-7-chloro-3H- quinazolin-4-one;
MS calc: 458.0 found: 458.2;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-biphenyl-4-yl-6-methoxy-3H- quinazolin-4-one;
MS calc: 453.6 found: 454.2;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-biphenyl-4-yl-3H-quinazolin-4-one; MS calc: 423.6 found: 424.2.
Example 10:
Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with thiophene-3-carbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained with R' = 3-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-thiophenyl-3-yl-6-chloro-3H- quinazolin-4-one;
MS calc: 387.9 found: 388.2;
with R' = 3-CH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-thiophenyl-3-yl-6-methyl-3H- quinazolin-4-one;
MS calc: 367.5 found: 368.2;
with R' = 4-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-thiophenyl-3-yl-7-chloro-3H- quinazolin-4-one;
MS calc: 387.9 found: 388.2;
with R' = 3-OCH3 in formuia lla
3-(3-aminomethyl-cyclohexyimethyl)-2-thiophenyl-3-yl-6-methoxy-3H- quinazolin-4-one;
MS calc: 383.5 ; found: 384.2;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-thiophenyl-3-yl-3H-quinazolin-4-one; MS calc: 353.5 found: 354.2.
Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with thiophene-2-carbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained
with R' = 3-CI in formula lla 3-(3-aminomethyl-cyclohexylmethyl)-2-thiophenyl-2-yl-6-chioro-3H- quinazolin-4-one;
MS calc: 387.9 found: 388.2;
with R' = 3-CH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-thiophenyl-2-yl-6-methyl-3H- quinazolin-4-one;
MS calc: 367.5 found: 368.2;
with R' = 4-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-thiophenyl-2-yl-7-chloro-3H- quinazoiin-4-one;
MS calc: 387.9 found: 388.1 ;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-thiophenyl-2-yl-6-methoxy-3H- quinazolin-4-one;
MS calc: 383.5 found: 384.2;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-thiophenyl-2-yl-3H-quinazolin-4-one; MS calc: 353.5 found: 354.2.
Example 11 : Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with naphthalene-2-carbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained
with R' = 3-CI in formula lla 3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-2-yl-6-chloro-3H- quinazolin-4-one;
MS calc: 432.0 found: 432.2;
with R' = 3-CH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-2-yl-6-methyl-3H- quinazolin-4-one;
MS calc: 411.6 found: 412.2;
with R' = 4-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-2-yl-7-chloro-3H- quinazolin-4-one;
MS calc: 432.0 found: 432.2;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-2-yl-6-methoxy-3H- quinazolin-4-one;
MS calc: 427.6 found: 428.2;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-2-yl-3H-quinazolin-4- one;
MS calc: 397.5 found: 398.2.
Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with naphthalene-1-carbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained
with R' = 3-CI in formula lla 3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-1-yl-6-chloro-3H- quinazolin-4-one;
MS calc: 432.0 found: 432.2;
with R' = 3-CH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-1-yl-6-methyl-3H- quinazolin-4-one;
MS calc: 411.6 found: 412.2;
with R' = 4-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-1-yl-7-chloro-3H- quinazolin-4-one;
MS calc: 432.0 found: 432.2;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-1-yl-6-methoxy-3H- quinazolin-4-one;
MS calc: 427.6 found: 428.2;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-1-yl-3H-quinazoiin-4- one;
MS calc: 397.5 found: 398.2.
Example 12:
Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with 3- phenyi-propenal, oxidation and cleavage from the solid phase, the following compounds are obtained with R' = 3-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-styryl-6-chloro-3H-quinazolin-4-one; MS calc: 407.9 found: 408.2;
with R' = 3-CH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-styryl-6-methyl-3H-quinazolin-4-one; MS calc: 387.5 found: 388.3;
with R' = 4-CI in formula lla 3-(3-aminomethyl-cyclohexylmethyl)-2-styryl-7-chloro-3H-quinazolin-4-one;
MS calc: 407.9 found: 408.2;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-styryl-6-methoxy-3H-quinazolin-4- one;
MS calc: 403.5 found: 404.3;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-styryl-3H-quinazolin-4-one; MS calc: 373.5 found: 374.3.
Example 13: Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with benzofuran-5-carbaldehyde, oxidation and cleavage from the solid phase, the following compounds are obtained
with R! = 3-CI in formula lla 3-(3-aminomethyl-cyclohexylmethyl)-2-benzofuran-5-yl-6-chloro-3H- quinazolin-4-one;
MS calc: 421.9 found: 422.2;
with R' = 3-CH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-benzofuran-5-yl-6-methyl-3H- quinazolin-4-one;
MS calc: 401.5 found: 402.2;
with R' = 4-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-benzofuran-5-yl-7-chloro-3H- quinazolin-4-one;
MS calc: 421.9 found: 422.2;
with R" = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexyimethyl)-2-benzofuran-5-yl-6-methoxy-3H- quinazolin-4-one;
MS calc: 417.5 found: 418.1 ;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-benzofuran-5-yl-3H-quinazolin-4- one;
MS calc: 387.5 found: 388.2.
Example 14:
Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with 3-(4- dimethylamino-phenyl)-propenal, oxidation and cleavage from the solid phase, the following compounds are obtained with R" = 3-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-[2-(4-dimethylamino-phenyl)-vinyl]-6- chloro-3H-quinazolin-4-one;
MS calc: 451.0;
with R' = 3-CH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-[2-(4-dimethylamino-phenyl)-vinyl]-6- methyl-3H-quinazolin-4-one; MS calc: 430.6;
with R' = 4-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-[2-(4-dimethylamino-phenyl)-vinyl]-7- chloro-3H-quinazolin-4-one; MS calc: 451.0;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-[2-(4-dimethylamino-phenyl)-vinyl]-6- methoxy-3H-quinazolin-4-one; MS calc: 446.6;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-[2-(4-dimethylamino-phenyl)-vinyl]- 3H-quinazolin-4-one; MS calc: 416.6.
Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with 3-(2,5- dimethoxy-phenyl)-propenal, oxidation and cleavage from the solid phase, the following compounds are obtained with R' = 3-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-[2-(2,5-dimethoxy-phenyl)-vinyl]-6- chloro-3H-quinazolin-4-one;
with R' = 3-CH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-[2-(2,5-dimethoxy-phenyl)-vinyl]-6- methyl-3H-quinazolin-4-one;
with R' = 4-CI in formula lla 3-(3-aminomethyl-cyclohexylmethyl)-2-[2-(2,5-dimethyoxy-phenyl)-vinyl]-7- chloro-3H-quinazolin-4-one;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-[2-(2,5-dimethoxy-phenyl)-vinyl]-6- methoxy-3H-quinazoiin-4-one;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-[2-(2,5-dimethoxy-phenyl)-vinyl]-3H- quinazolin-4-one.
Example 15:
Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with 4- bromo-benzaldehyde, Suzuki-reaction with 2,4-dimethoxyphenyl boronic acid as indicated afterwards, oxidation and cleavage from the solid phase, the following compounds are obtained
with R' = 3-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-(2',4'-dimethoxy-biphenyl-4-yl)-6- chloro-3H-quinazolin-4-one; with R' = 3-CH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-(2',4'-dimethoxy-biphenyl-4-yl)-6- methyl-3H-quinazolin-4-one;
with R' = 4-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-(2',4'-dimethoxy-biphenyl-4-yl)-7- chloro-3H-quinazolin-4-one;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyi-cyclohexylmethyl)-2-(2',4'-dimethoxy-biphenyl-4-yl)-6- methoxy-3H-quinazolin-4-one;
with R' = H in formula lla 3-(3-aminomethyl-cyclohexylmethyl)-2-(2',4'-dimethoxy-biphenyl-4-yl)-3H- quinazolin-4-one.
Suzuki reaction according to G.C. Fu et al., Angew. Chem. 1998, 110,
3586-3587:
1 gram of resin bound 3-(3-aminomethyl-cyclohexylmethyl)-2-(4- bromophenyl)-3H-quinazolin-4-one is suspended in 10 ml of 1 ,4-dioxane.
The reaction is then treated with 1.62 mmol Cs2CO3, 1.62 mmol of 2,4- dimethoxyphenyl boronic acid and 10 mol% ([Pd2(dba)3] + P(tert-Bu)3). The reaction is then allowed to shake at 80° until conversion is complete. After cooling the reaction mixture, it is worked up as is customary.
Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with 4- bromo-benzaldehyde, Suzuki-reaction with 3,5-dimethoxypheny! boronic acid as indicated afterwards, oxidation and cleavage from the solid phase, the following compounds are obtained
with R' = 3-CI in formula lla 3-(3-aminomethyl-cyclohexylmethyl)-2-(3',5'-dimethoxy-biphenyl-4-yl)-6- chloro-3H-quinazolin-4-one;
with R' = 3-CH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-(3',5'-dimethoxy-biphenyl-4-yl)-6- methyl-3H-quinazolin-4-one;
with R' = 4-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-(3',5'-dimethoxy-biphenyl-4-yl)-7- chloro-3H-quinazolin-4-one;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-(3',5'-dimethoxy-biphenyl-4-yl)-6- methoxy-3H-quinazolin-4-one;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-(3',5'-dimethoxy-biphenyl-4-yl)-3H- quinazolin-4-one.
Analogously to example 2, by reaction of resin (2) with a compound of formula lla, cleavage of the Fmoc protecting group and reaction with 5- bromo-thiophenyl-2-carbaldehyde, Suzuki-reaction with 3,4- dimethoxyphenyl boronic acid as indicated afterwards, oxidation and cleavage from the solid phase, the following compounds are obtained
with R' = 3-CI in formula lla 3-(3-aminomethyl-cyclohexylmethyl)-2-[5-(2,4-dimethoxy-phenyl)-2- thiophenyl]-6-chloro-3H-quinazolin-4-one;
with R' = 3-CH3 in formula lla 3-(3-aminomethyl-cyclohexylmethyl)-2-[5-(2,4-dimethoxy-phenyl)-2- thiophenyl]-6-methyl-3H-quinazolin-4-one;
with R' = 4-CI in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-[5-(2,4-dimethoxy-phenyl)-2- thiophenyl]-7-chloro-3H-quinazolin-4-one;
with R' = 3-OCH3 in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-[5-(2,4-dimethoxy-phenyl)-thiophen- 2-yl]-6-methoxy-3H-quinazolin-4-one;
with R' = H in formula lla
3-(3-aminomethyl-cyclohexylmethyl)-2-[5-(2,4-dimethoxy-phenyl)-thiophen-
2-yl]-3H-quinazolin-4-one.
The following examples relate to pharmaceutical preparations:
Example A: Injection vials
A solution of 100 g of an active compound of the formula I and 5 g of disodium hydrogenphosphate is adjusted to pH 6.5 in 3 I of double-distilled water using 2N hydrochloric acid, sterile-filtered, dispensed into injection vials, lyophilized under sterile conditions and aseptically sealed. Each injection vial contains 5 mg of active compound. Example B: Suppositories
A mixture of 20 g of an active compound of the formula I is melted with
100 g of soya lecithin and 1400 g of cocoa butter, poured into moulds and allowed to cool. Each suppository contains 20 mg of active compound.
Example C: Solution
A solution is prepared from 1 g of an active compound of the formula I,
9.38 g of NaH2PO4.2H2O, 28.48 g of Na2HPO4.12H2O and 0.1 g of benzalkonium chloride in 940 ml of double-distilled water. The mixture is adjusted to pH 6.8, made up to 1 I and sterilized by irradiation. This solution can be used in the form of eye drops.
Example D: Ointment
500 mg of an active compound of the formula I is mixed with 99.5 g of petroleum jelly under aseptic conditions.
Example E: Tablets
A mixture of 1 kg of active compound of the formula I, 4 kg of lactose, 1.2 kg of potato starch, 0.2 g of talc and 0.1 kg of magnesium stearate is compressed in a customary manner to give tablets such that each tablet contains 10 mg of active compound.
Example F: Coated tablets
Analogously to Example E, tablets are pressed which are then coated with a coating of sucrose, potato starch, talc, tragacanth and colourant in a customary manner.
Example G: Capsules
2 kg of active compound of the formula I are dispensed into hard gelatin capsules in a customary manner such that each capsule contains 20 mg of the active compound. Example H: Ampules
A solution of 1 kg of active compound of the formula I in 60 ml of double- distilled water is sterile-filtered, dispensed into ampoules, lyophilized under sterile conditions and aseptically sealed. Each ampoule contains 10 mg of active compound.

Claims

What is claimed is:
1 . Compounds of the formula
Figure imgf000058_0001
in which
R and R are independently of each other H, A, OH, OA, OCH2-Ar, Hal, NH2, NHA, NA2, NO2, CN, C(O)R2, CONH2, CONHA, CONA2,
COOH, COOA or SO2A, R2 and R3 are independently of each other H, A, -C(=NH)-NH2 or solid phase, R4 is Ar, phenylalkyl, cycloalkyl or Het, Y may be absent and, if present, is alkenyl having 2 to 4 carbon atoms, A is unbranched or branched alkyl having 1 to 6 carbon atoms,
Ar is phenyl, naphthyl, biphenyl or benzofuranyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF3, OCF3, Hal, CN, COOH, COOA, NH2, NHA, NA2, NO2,
SO2NH2, SO2NAH or SO2NA2, Het is a saturated, partially or completely unsaturated mono- or bicyclic heterocyclic radical having 5 to 10 ring members, where 1 or 2 N and/or 1 or 2 S or O atoms can be present and the heterocyclic radical can be mono- or disubstituted by A,
Hal, OH, OA, CF3, OCF3, NH2, NHA, NA2, COOH, COOA, phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF3, OCF3, Hal, CN, COOH, COOA, NH2, NHA, NA2, NO2, SO2NH2, SO2NAH or SO2NA2 or thiophenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF3, OCF3, Hal, CN, COOH, COOA, NH2, NHA, NA2, NO2,
SO2NH2, SO2NAH or SO2NA2, Hal is F, Cl, Br or l, n is 0, 1 , 2 or 3, m is 0, 1 , 2 or 3, and their pharmaceutically tolerable salts and solvates.
2. Compounds of the formula I according to Claim 1 a) 3-(3-aminomethyl-cyclohexylmethyl)-2-[2,2']bithiophenyl-5-yl-6- methoxy-3H-quinazolin-4-one, b) 3-(3-aminomethyl-cyclohexylmethyl)-2-naphthaleπ-1-yl-6-methoxy-3H- quinazolin-4-one; c) 3-(3-aminomethyi-cyclohexylmethyl)-2-naphthalen-1-yl-6-methyl-3H- quinazoiin-4-one; d) 3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-1 -yl-3H-quinazolin-
4-one; e) 3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-2-yl-6-methoxy-3H- quinazolin-4-one; f) 3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-2-yl-3H-quinazolin- 4-one; g) 3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-2-yl-6-methyl-3H- quinazolin-4-one; h) 3-(3-aminomethyl-cyclohexylmethyl)-6-chloro-2-naphthalen-2-yl-3H- quinazolin-4-one; i) 3-(3-aminomethyl-cyclohexylmethyl)-7-chloro-2-naphthalen-2-yl-3H- quinazolin-4-one; and their physiologically acceptable salts and solvates.
3. Process for the preparation of the compounds of the formula I according to Claim 1 and their salts or solvates, characterized in that a) a compound of the formula I is liberated from one of its functional derivatives by treating with a solvolysing or hydrogenolysing agent, or b) in stage 1) a compound of the formula II
Figure imgf000060_0001
in which
X is Cl, Br, OH or a reactive ester ified OH group and
Q is NH2 or NHA, either of which is optionally protected, and
R and R1 are optionally protected when they are or contain NH2 or NHA, is reacted with a compound of the formula III
Figure imgf000060_0002
in which R2, R3, n and m have the meanings indicated in Claim 1 , to give a compound of forumula IV
Figure imgf000060_0003
in which R, R1, R2, R3, Q, n and m have the meanings indicated above, and in stage 2) a compound of formula IV as indicated above is if necessary deprotected to give a compound of formula IV in which Q is NH2 or NHA and is reacted with a compound of formula V
R4-Y-CHO V in which R4 and Y have the meanings indicated in Claim 1 , or c) a radical R, R1, R2, R3 and/or R4 is converted into another radical R, R1, R2, R3 and/or R4 by, for example converting an amino group into a guanidino group by reaction with an amidinating agent, - reducing a nitro group, sulfonyl group or sulfoxyl group, etherifying an OH group or subjecting an OA group to ether cleavage, alkylating a primary or secondary amino group, partially or completely hydrolysing a CN group, - cleaving an ester group or esterifying a carboxylic acid radical, reacting an aryl bromide, aryl iodide, heteroaryl bromide or heteroaryliodide to give the corresponding coupling products by means of a Suzuki coupling with boronic acids, or carrying out a nucleophilic or electrophiiic substitution, and/or
(e) a base or acid of the formula I is converted into one of its salts or solvates.
4. Compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates as pharmaceutical active compounds.
5. Compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates as glycoprotein IblX antagonists.
6. Compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates as glycoprotein IblX antagonists for the control of thrombotic disorders and sequelae deriving therefrom.
7. Pharmaceutical preparation characterized in that it contains at least one compound of the formula I according to Claim 4 and/or one of its physiologically acceptable salts or solvates.
8. Use of compounds of the formula I according to Claim 1 and/or their physiologically acceptable salts or solvates for the production of a pharmaceutical preparation for the control of thrombotic disorders and sequelae deriving therefrom or for use as anti-adhesive substances.
9. Use of compounds of the formula I according to Claim 4 and/or their physiologically acceptable salts or solvates for the production of a pharmaceutical preparation for the treatment of illnesses, such as for the prophylaxis and/or therapy of thrombotic disorders, as well as sequelae such as, for example, myocardial infarct, arteriosclerosis, angina pectoris, acute coronary syndromes, peripheral circulatory disorders, stroke, transient ischaemic attacks, reocclusion/restenosis after angioplasty/stent implantations or as anti-adhesive substances for implants, catheters or heart pacemakers.
PCT/EP2000/008939 1999-09-28 2000-09-13 Quinazolinones WO2001023364A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US10/089,167 US7060706B1 (en) 1999-09-28 2000-09-13 Quinazolinones
KR1020027003906A KR20020047185A (en) 1999-09-28 2000-09-13 Quinazolinones
BR0014311-1A BR0014311A (en) 1999-09-28 2000-09-13 Quinazolinones
CA002385918A CA2385918A1 (en) 1999-09-28 2000-09-13 Quinazolinones
EP00962482A EP1216233A1 (en) 1999-09-28 2000-09-13 Quinazolinones
AU74193/00A AU7419300A (en) 1999-09-28 2000-09-13 Quinazolinones
NO20021503A NO20021503D0 (en) 1999-09-28 2002-03-26 quinazolinones

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40793999A 1999-09-28 1999-09-28
US09/407,939 1999-09-28

Publications (1)

Publication Number Publication Date
WO2001023364A1 true WO2001023364A1 (en) 2001-04-05

Family

ID=23614192

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/008939 WO2001023364A1 (en) 1999-09-28 2000-09-13 Quinazolinones

Country Status (8)

Country Link
EP (1) EP1216233A1 (en)
KR (1) KR20020047185A (en)
AR (1) AR025796A1 (en)
AU (1) AU7419300A (en)
BR (1) BR0014311A (en)
CA (1) CA2385918A1 (en)
NO (1) NO20021503D0 (en)
WO (1) WO2001023364A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7671200B2 (en) 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US7687625B2 (en) 2003-03-25 2010-03-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7723344B2 (en) 2003-08-13 2010-05-25 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7763628B2 (en) 1999-10-27 2010-07-27 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7781584B2 (en) 2004-03-15 2010-08-24 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8084605B2 (en) 2006-11-29 2011-12-27 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011438A1 (en) * 1996-09-13 1998-03-19 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011438A1 (en) * 1996-09-13 1998-03-19 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008311B2 (en) 1999-10-27 2011-08-30 Cytokinetics, Inc. Methods and compostions utilizing quinazolinones
US6562831B1 (en) 1999-10-27 2003-05-13 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6630479B1 (en) 1999-10-27 2003-10-07 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6831085B1 (en) 1999-10-27 2004-12-14 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7671200B2 (en) 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US7763628B2 (en) 1999-10-27 2010-07-27 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US8470838B2 (en) 1999-10-27 2013-06-25 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7687625B2 (en) 2003-03-25 2010-03-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7723344B2 (en) 2003-08-13 2010-05-25 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7790736B2 (en) 2003-08-13 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8188275B2 (en) 2004-03-15 2012-05-29 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7906523B2 (en) 2004-03-15 2011-03-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8173663B2 (en) 2004-03-15 2012-05-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7807689B2 (en) 2004-03-15 2010-10-05 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8288539B2 (en) 2004-03-15 2012-10-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8329900B2 (en) 2004-03-15 2012-12-11 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7781584B2 (en) 2004-03-15 2010-08-24 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8084605B2 (en) 2006-11-29 2011-12-27 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors

Also Published As

Publication number Publication date
NO20021503L (en) 2002-03-26
AU7419300A (en) 2001-04-30
EP1216233A1 (en) 2002-06-26
CA2385918A1 (en) 2001-04-05
NO20021503D0 (en) 2002-03-26
BR0014311A (en) 2002-05-21
KR20020047185A (en) 2002-06-21
AR025796A1 (en) 2002-12-11

Similar Documents

Publication Publication Date Title
EP1318984A1 (en) 4-amino-quinazolines
WO2001023364A1 (en) Quinazolinones
NZ318926A (en) Alpha v beta 3 integrin (vitronectin) inhibitors or anatagonists derived from benzoic acid for treating diseases of cell adhesion
US20040044204A1 (en) 4-amino-quinazolines
EP1133475A1 (en) Substituted benzo de]isoquinoline-1,3-diones
SK11732001A3 (en) Beta-alanine derivatives
EP1144381A2 (en) Substituted benzo[de]isoquinoline-1,3-diones
EP1216235A1 (en) Quinazolinones
EP1343764B1 (en) Urea and urethane derivatives as integrin inhibitors
US6890930B1 (en) Quinazolinones
US7060706B1 (en) Quinazolinones
SK192002A3 (en) Diacylhydrazine derivatives, process for the preparation and use thereof and pharmaceutical composition comprising same
US7829566B2 (en) 4-amino-quinazolines
US6521646B1 (en) Dibenzoazulene derivatives for treating thrombosis, osteoporosis, arteriosclerosis
US20030187289A1 (en) Biphenyl derivatives and the use thereof as integrin inhibitors
JP2003506439A (en) Fluorene derivative

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000962482

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020027003906

Country of ref document: KR

Ref document number: 2385918

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1020027003906

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000962482

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10089167

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000962482

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP